While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination ...

Multiple sclerosis (MS) is a chronic autoimmune disease affecting more than 2.9 million people worldwide. It occurs when the ...

Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from ...

Detailed price information for Quantum Biopharma Ltd (QNTM-Q) from The Globe and Mail including charting and trades.

- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton’s Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of ...

Anthony Durkacz, Executive Co-Chairman of Quantum BioPharma added, “We are very excited about the potential of Lucid-MS as a first-in-class treatment for MS targeting demyelination. With these final ...

In a new study, researchers found that increased expression of gene PRDM1-S triggers loss of immune regulation in autoimmune conditions like multiple sclerosis (MS). The findings could pave the way ...

The lab is using AI to analyze complex biomedical data to improve drug development for many diseases, including MS and ...

Sept 2 (Reuters) - Sanofi's (SASY.PA), opens new tab most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a ...

The agreement grants Zenas global development and commercialization rights to orelabrutinib for Multiple Sclerosis and all therapeutic areas outside oncology. Additionally, Zenas secured rights to a ...

FRANKFURT, Jan 13 (Reuters) - Merck KGaA said on Tuesday it had bought the rights to develop and market an experimental multiple sclerosis (MS) drug from British biotech company Apitope, expanding its ...